To address the biological role of this lncRNA, the authors first subdivided patients into clinically relevant groups according to either the expression levels of CDK6-AS1 or the genetic abnormalities identified in AML at diagnosis. The gene discussed is CDK6; the disease is acute myeloid leukemia.